The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•26 March 2026•

1 min read

Neurocrine Biosciences Issues First Expert Consensus for Tardive Dyskinesia in Long-Term Care

Key Facts

1Neurocrine Biosciences presented the first expert consensus recommendations focused on screening, diagnosis, and treatment of tardive dyskinesia in long-term care settings.

Neurocrine Biosciences (NBIX) has announced the first-ever expert consensus recommendations for the screening, diagnosis, and treatment of tardive dyskinesia (TD) in long-term care settings. Developed by a multidisciplinary Delphi panel, these guidelines aim to address critical gaps in managing the condition among older populations. Alongside the recommendations, the company shared new analysis from the KINECT-PRO study demonstrating significant clinical improvements in patients aged 65 and older. The data specifically highlights the efficacy of INGREZZA (valbenazine) capsules in treating TD symptoms within this high-risk demographic. This dual announcement reinforces the clinical validity of INGREZZA as a primary treatment option for geriatric patients. Market analysts view this development as a positive step for NBIX, as it expands the drug's clinical footprint in the long-term care market.